Viral vector integration sites profile in clinical CAR/TCR T-cell products
Clinical CAR T-cell therapy using integrating vector systems represents a promising approach for the treatment of hematological malignancies. Lentiviral and gamma-retroviral vectors are the most commonly used vectors in the manufacturing process. However, the integration pattern of these viral vectors and subsequent effect on CAR T-cell products is still unclear. We used a modified viral integration sites analysis (VISA) pipeline to evaluate viral integration events around the whole genome in infusion CAR/TCR T-cell products. We compared the differences of integration pattern between lentiviral and gamma-retroviral products.